Pharmaceutical translation represents one of the most specialized and strictly regulated sectors in language services. Precision is paramount — any inaccuracy or deviation from approved terminology can lead to dossier rejection by regulatory authorities (SUKL, EMA, FDA) or even compromise patient safety.
- Pharmaceutical translations must adhere strictly to mandatory EMA QRD templates and European Pharmacopoeia (Ph. Eur.) terminology.
- Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PIL) require different writing styles and terminology, as they are intended for distinct audiences — healthcare professionals and patients.
- Clinical trial documentation often requires a multi-stage quality assurance process, including back-translation, reconciliation and independent review to ensure linguistic accuracy and regulatory compliance.
1. Primary Categories of Pharmaceutical Documentation
We process a broad spectrum of pharmaceutical and healthcare documents. Each document type carries unique demands regarding style, structure, and target audience:
- Summary of Product Characteristics (SmPC / SPC) — Official prescribing information for healthcare professionals requiring strict adherence to official medical terminology.
- Patient Information Leaflet (PIL) — Patient-friendly information on safe usage, warnings, and dosage instructions. Requires clear, accessible language compliant with readability guidelines.
- Registration Dossiers (Dossier / eCTD) — Comprehensive regulatory submissions (eCTD, NeeS, CTD formats) containing chemical, pharmaceutical, biological, and clinical data for marketing authorization.
- Clinical Trials & Protocols — Informed Consent Forms (ICF), Case Report Forms (CRF),clinical trial protocols, and adverse event reports.
- Packaging Materials — Cartons, labels, blister packs, package inserts and artwork requiring precise DTP, terminology consistency and compliance with space limitations.
Did you know? When submitting documentation to regulatory authorities such as the State Institute for Drug Control (SUKL) or the European Medicines Agency (EMA), translations must adhere verbatim to the current version of QRD (Quality Review of Documents) templates. Non-compliance leads to immediate application rejection.
2. Regulatory Standards & Regulatory Authorities
The authorization process for medicinal products in European and international markets is governed by strictly defined legislative frameworks. Below is an overview of key regulatory bodies and normative standards:
| Authority / Standard | Jurisdiction | Key Translation Requirements |
|---|---|---|
| SUKL (Czech Republic) | Czech Market | Czech terminology aligned with the Czech Pharmacopoeia and SUKL guidelines. |
| EMA (European Union) | EU / EEA Market | Strict compliance with official QRD templates across all 24 official EU languages. |
| FDA (United States) | US Market | Structural alignment with the US Pharmacopeia (USP) and 21 CFR regulations. |
| ISO 17100 | International Standard | Mandatory two-stage process: expert translation + independent revision. |
3. Quality Assurance Process & Back-Translation
For high-risk documentation, such as Patient Informed Consent Forms in clinical trials, a process known as Back-Translation is deployed. This workflow comprises four steps:
- Primary Translation: A medical translator translates the source text into the target language.
- Back-Translation: An independent translator, blinded to the original text, translates the target text back into the source language.
- Reconciliation Analysis: A project manager and medical reviewer compare the original source with the back-translation to identify any semantic discrepancies.
- Final Consensus: Creation of an error-free final version accompanied by an official certificate of accuracy.